Ondine Biomedical
Ondine Biomedical (LSE: OBI) is a Vancouver-based clinical-stage life sciences company that has commercialized Steriwave™, a CE-marked, FDA Fast Track-designated photodisinfection nasal decolonization therapy that reduces surgical site infections without contributing to antimicrobial resistance, sold to hospitals across Canada, the UK, and selected international markets.
- Company typePublic
- Founded1999
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ondine Biomedical does
Ondine Biomedical Inc. is a Canadian clinical-stage life sciences company headquartered in Vancouver, British Columbia, and listed on the AIM market of the London Stock Exchange (ticker: OBI) since December 2021. The company has built a patented photodisinfection platform — an antimicrobial photodynamic therapy (aPDT) that applies a photosensitizing solution to a treatment site and activates it with non-thermal laser light, generating singlet oxygen that destroys pathogens through oxidative burst; the reaction ceases immediately when the light source is removed. The lead commercial product, Steriwave™, is a rapid nasal decolonization system that eradicates Staphylococcus aureus, MRSA, Candida auris, SARS-CoV-2 and related pathogens in a single five-minute, nurse-administered pre-surgical treatment, eliminating the patient-compliance burden of multi-day topical antibiotic protocols.
Steriwave is CE-marked in Europe, holds FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for the United States, and is classified as an Innovation Product by NHS Supply Chain in the United Kingdom. Real-world clinical outcomes range from a 66% to 84% reduction in surgical site infections across cohorts including Vancouver General Hospital (10-year longitudinal data), Leeds Teaching Hospitals (78.5% reduction in complex brain surgery), and Mid Yorkshire Teaching NHS Trust (71% reduction). The company is currently running the pivotal Phase 3 LANTERN trial under FDA review, with 93%+ enrollment across 14 HCA Healthcare sites and four Canadian centers (5,200+ patients) and top-line results expected in Spring 2026.
Ondine generates revenue from sales of Steriwave capital equipment and recurring per-procedure consumables into hospitals, with FY2025 revenue of CAD 2.6 million (~29% YoY growth) and a customer footprint of 37 hospitals across Canada, the United Kingdom, and international pilot markets (Spain, Germany, Mexico). Distribution is primarily direct in Canada and through Mölnlycke Health Care in the United Kingdom, with HCA Healthcare acting as both a clinical-development partner for the US Phase 3 program and as a UK commercial channel. Beyond Steriwave, Ondine has four pipeline indications — chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection to prevent ventilator-associated pneumonia, and topical antiviral therapy for upper respiratory viruses — which extend the platform TAM but contribute no current revenue. The company has reported a CAD 29.5 million net loss in FY2025, driven principally by over CAD 21 million in LANTERN trial R&D spend.
Ondine Biomedical firmographics
Firmographics- Name
- Ondine Biomedical
- Legal name
- Ondine Biomedical Inc.
- Website
- https://ondinebio.com
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Ondine Biomedical (LSE: OBI) is a Vancouver-based clinical-stage life sciences company that has commercialized Steriwave™, a CE-marked, FDA Fast Track-designated photodisinfection nasal decolonization therapy that reduces surgical site infections without contributing to antimicrobial resistance, sold to hospitals across Canada, the UK, and selected international markets.
- Ownership category
- akta.pro rank
Ondine Biomedical industry classification
Industry- Product category
- Antimicrobial medical devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots) (HLAHANAD)
Keywords
Where Ondine Biomedical is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Ondine Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Steriwave Device and Consumables Sales: Sale of Steriwave photodisinfection system (capital equipment) and associated consumable components for nasal photodisinfection treatments. Revenue generated from hospital deployments and per-procedure consumables. FY2025 revenue was CAD 2.6 million with 29% year-over-year growth, driven by expanding hospital customer base.
- Product Pipeline Development: Development-stage products include chronic rhinosinusitis treatment, burn/wound decolonization, endotracheal tube disinfection for ventilator-associated pneumonia prevention, and topical antiviral therapy for upper respiratory tract including SARS-CoV-2. These pipeline products represent future revenue potential as they receive regulatory approvals.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels4 records
Ondine Biomedical product offering
Product offeringCore offering
Ondine Biomedical develops and commercializes Steriwave, a light-activated antimicrobial photodisinfection medical device that performs rapid 5-minute nasal decolonization to eliminate pathogens (bacteria, viruses, fungi including MRSA, Staphylococcus aureus, Candida auris, and SARS-CoV-2) associated with healthcare-associated infections. The proprietary platform combines a photosensitizing solution with non-thermal laser light at specific wavelengths to generate singlet oxygen that destroys pathogens through oxidative burst without contributing to antimicrobial resistance. The product is sold as capital equipment together with per-procedure consumables to hospitals and healthcare systems for pre-surgical and ICU infection prevention.
Product overview
Ondine Biomedical Inc. is a Canadian life sciences company that has developed a patented photodisinfection platform technology for preventing and treating infections. The company's lead commercial product is Steriwave™, a rapid nasal decolonization therapy that eradicates pathogens in minutes using light-activated antimicrobial technology. The technology has been deployed in Canadian and UK hospitals, demonstrating up to 84% reduction in surgical site infections. The company also maintains a pipeline of products in development including treatments for chronic rhinosinusitis, burn and wound decolonization, endotracheal tube disinfection for ventilator-associated pneumonia prevention, and topical antiviral therapy for upper respiratory tract infections.
Differentiator
Problem solved
Functional benefit
Brands
- Steriwave™: Rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics.
Products and services
- Steriwave Nasal Photodisinfection System Steriwave is a light-activated antimicrobial medical device that performs rapid 5-minute nasal decolonization to eradicate a broad spectrum of pathogens (Staphylococcus aureus, MRSA, Candida auris, SARS-CoV-2 and other superbugs) in the nose. Designed for nurse-led in-clinic administration in hospitals, it eliminates pathogens associated with healthcare-associated infections without contributing to antimicrobial resistance. Real-world deployments at Vancouver General Hospital demonstrated up to 84% reduction in surgical site infections over the past decade.
Quantifiable outcome
- Up to 84% reduction in surgical site infections at Vancouver General Hospital over past decade
- +5 more outcomes
Companies that use Ondine Biomedical
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
Ondine Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Ondine Biomedical partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor and core.
- LMU University Hospital MunichminorResearch collaboration with Europe's highly ranked medical institution to pilot Steriwave in ENT patients, marking first German hospital pilot.
- Royal Papworth Hospital NHS Foundation TrustminorRoyal Papworth Hospital, one of the world's foremost cardiothoracic centres, launching pilot program with Steriwave for complex cardiac surgeries.
- CAN Health NetworkminorMembership in CAN Health Network provides strategic support, insights and connections as Ondine works to scale its infection prevention technology across Canada.
- Royal Columbian Hospital FoundationcorePartnership for ICU pilot study (SMURF) evaluating nasal photodisinfection in critically ill patients. Study results accepted for publication in Journal of Critical Care, marking first-ever deployment of this therapy in ICU setting. Foundation provided research support and funding.
- Leeds Teaching Hospitals NHS TrustcoreDr. Paul Nix-led study at Leeds demonstrated 78.5% reduction in SSIs in complex brain surgery. Study results accepted for publication in Journal of Laryngology & Otology. Funded in part by Leeds Hospitals Charity.
- HCA Healthcare UKcoreHCA Healthcare UK, one of the UK's leading private healthcare providers operating 30+ facilities, authorized Steriwave for use across its healthcare facilities. Professor Claire Hopkins at London Bridge Hospital demonstrated a 77% reduction in antibiotic use in endoscopic sinus surgery patients.
- HCA HealthcarecoreHCA Healthcare is a key strategic partner conducting the pivotal Phase 3 LANTERN clinical trial across 14 US hospitals with over 5,200 patients. HCA invested US$4 million in Ondine and is partnered for FDA regulatory submission. HCA Healthcare is the largest healthcare system in the US with 184 hospitals and 2,000+ sites of care.
- Mölnlycke Health CarecoreMölnlycke Health Care serves as the UK distribution partner for Steriwave following partnership announced September 2023. Mölnlycke distributes the technology to NHS providers through NHS Supply Chain, enabling broad UK market access.
- Mid Yorkshire Teaching NHS TrustcorePartnership deploying Steriwave at two hospitals resulted in 71% reduction in post-surgical infections. Partnership won Excellence in Healthcare Partnership Award and shortlisted for HSJ Partnership Award. Technology now being evaluated across hospitals in England.
Scale indicators13 records
Recent moves7 records
Expansion highlights6 records
Ondine Biomedical competitors and assessment
Company assessmentDirect peers
- PDI (Professional Disposables International): PDI's Prevantics and other nasal antiseptic products directly compete with Steriwave in the pre-surgical nasal decolonization category, targeting the same hospital infection-prevention buyers and similar clinical indications. Both compete for SSI reduction protocols in US hospitals.
Broad incumbents
- Steris: Steris is a large, publicly-listed sterilization and infection-prevention company serving hospitals and life sciences with capital equipment, consumables, and services. It is an incumbent comparator for any hospital-grade antimicrobial/sterilization technology play, including Steriwave's infection-prevention value proposition.
- 3M (Health Care): 3M's Health Care division sells skin and nasal antiseptics, surgical drapes, and infection-prevention products into the same hospital procurement channels as Steriwave. It is a broad incumbent competing for hospital infection-prevention budgets and SSI-reduction protocols.
- Clorox Healthcare: Clorox Healthcare is a major incumbent in healthcare environmental disinfection (wipes, bleach cleaners, UV systems) sold into the same hospital infection-prevention channels as Steriwave. Comparable as a broad disinfectant incumbent competing for hospital HAI-reduction budgets.
Others
- Mölnlycke Health Care: Mölnlycke is Ondine's UK distribution partner for Steriwave through NHS Supply Chain, and is itself a leading global wound care and infection-prevention company. Comparable as an infection-prevention participant serving hospitals, with direct overlap on the UK commercial channel.
Emerging players
- Noxilizer: Noxilizer provides nitrogen dioxide-based no-touch sterilization for medical devices and pharmaceutical manufacturing. Comparable as an emerging non-traditional antimicrobial technology company targeting healthcare infection-prevention use cases adjacent to Steriwave.
- Bioquell (Ecolab): Bioquell (now part of Ecolab) provides hydrogen peroxide vapor bio-decontamination systems for hospital rooms and life sciences facilities. Comparable as an emerging technology vendor in hospital infection prevention with overlap on HAI reduction value propositions.
- DenMat: DenMat has historically offered Periowave and other light-activated antimicrobial products in dentistry, using a related photodisinfection approach. It is the closest direct comparable in photodynamic antimicrobial therapy, though operating in dental rather than hospital infection prevention.
- Theralase Technologies: Theralase is a clinical-stage photodynamic therapy company developing light-activated therapeutics for cancer and infections. Comparable as a small-cap photodynamic therapy peer with similar scientific underpinnings to Ondine's photodisinfection platform.
Regional players
- Xttrium Laboratories: Xttrium manufactures antiseptic and skin-prep products including chlorhexidine applicators used in US hospital decolonization protocols. Comparable as a US-focused antiseptic manufacturer competing with Steriwave for the pre-surgical nasal decolonization indication.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Ondine Biomedical social profiles
Digital presenceOndine Biomedical compliance and trust
Trust signalCompliance3 records
Ondine Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ondine Biomedical leadership team
Management profileNumber of profiles
Profiles13 records
Ondine Biomedical funding detail
Funding detailFunding overview
Funding rounds7 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ondine Biomedical M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ondine Biomedical
What does Ondine Biomedical do?
Ondine Biomedical develops and commercializes Steriwave, a light-activated antimicrobial photodisinfection medical device that performs rapid 5-minute nasal decolonization to eliminate pathogens (bacteria, viruses, fungi including MRSA, Staphylococcus aureus, Candida auris, and SARS-CoV-2) associated with healthcare-associated infections. The proprietary platform combines a photosensitizing solution with non-thermal laser light at specific wavelengths to generate singlet oxygen that destroys pathogens through oxidative burst without contributing to antimicrobial resistance. The product is sold as capital equipment together with per-procedure consumables to hospitals and healthcare systems for pre-surgical and ICU infection prevention.
Is Ondine Biomedical a public or private company?
Ondine Biomedical is a public company. It is classified as public and is currently operating.
When was Ondine Biomedical founded?
Ondine Biomedical was founded in 1999. It employs 11 to 50 people.
Where is Ondine Biomedical based?
Ondine Biomedical is headquartered in Vancouver, Canada, in the North America region.
How does Ondine Biomedical make money?
Two revenue lines are on record. Steriwave Device and Consumables Sales are the primary driver. The others are product Pipeline Development.
Who are Ondine Biomedical's main competitors?
PDI (Professional Disposables International) is listed as a direct peer. Broad incumbents are Steris, 3M (Health Care) and Clorox Healthcare. Mölnlycke Health Care is listed as an others. Emerging players are Noxilizer, Bioquell (Ecolab), DenMat and Theralase Technologies. Xttrium Laboratories is listed as a regional player.
Does Ondine Biomedical have an API?
No public API is recorded for Ondine Biomedical.
What industry is Ondine Biomedical in?
Ondine Biomedical's product category is Antimicrobial medical devices. Its primary akta.pro industry code is HLAHANAD, Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots). Its NAICS code is 339112 and its SIC code is 3841.